Background: Mood disorders represent a major cause of morbidity and mortality worldwide but their pathophysiology remains obscure. Gene expression profiles, especially with regards to the interactive influence of genes within the expression profiles underlying pathological brain phenotypes associated with mood disorders remains largely undefined.
INTRODUCTION
Neurobiological blueprints for adaptive behavior are governed by genes, especially their coding regions, by mediating molecular processes critical for brain development and functions. These, in turn, bridge the functional gene expression effects on complex behavioral phenotypes.
Transcription factors (TFs) are sequence-specific DNA-binding proteins that are also known as regulatory proteins. TFs regulate the expression of genes by recognizing and binding to specific DNA regulatory elements called DNA binding domains in the promoter region of genes (Changeaux 2017; Lambert et al. 2018) . This attribute enables TFs to hierarchically regulate the expression of genes by controlling (i.e. promoting/activating or blocking/repressing) transcription of the adjacent structural genes into mRNA, and subsequently proteins (Changeaux 2017; Lambert et al. 2018) . TFs are therefore in a functional elevated status in the hierarchy of gene expression repertoires because they cooperatively, or synergistically regulate genes encoding other TFs (Lambert et al. 2018) . As such, TFs are thereby able to control transcription of their own and related structural genes (Kerszberg & Changeaux 1998; Changeaux 2017) . Consequently, nonlinear relationships arise from this functional complexity among genes, and intricate gene-gene interactions often create functionally co-operative gene assemblies of varying hierarchical gene expression programs essential for biological processes (Kerszberg & Changeaux 1998; Tsigelny et al. 2013 ).
Based on the complex but crucial role of thousands of transcription factors in controlling gene regulation, dysregulation of TF-mediated gene expression programs have been hypothesized to contribute to a broad range of diseases (Lee & Young 2013), including neuropsychiatric disorders (Lee & Young 2013; Nord AS, Pattabiraman K, Visel A & Rubinstein JLR 2015; Changeaux 2017; Torre-Ubieta et al. 2018) . The putative role of TF networks in mood disorder pathogenesis is however not well defined. Because mood disorders are the most common neuropsychiatric syndromes (Yizhar 2012) , and they collectively account for a high global burden of disease (Collins et al. 2010) , the role of TFs in anterior insula gene expression profiles associated with affective dysfunction was examined.
Adult brain gray matter volumetric reductions in the anterior insula have been consistently identified in mood disorders (Goodkind et al. 2015; Wise et al. 2016) . Such reduced gray matter volumes are predictive of cognitive impairment and affective dysfunction in both major depressive disorder and bipolar disorder (McTeague et al. 2017) . Functional magnetic resonance imaging (fMRI) of the right anterior insula region has been reported to selectively predict the therapeutic response to psychotherapy and pharmacotherapy (McGrath et al. 2013 ). The current study tested the hypothesis that transcription factor gene expression profiles are altered in the postmortem anterior insula cortex of mood disorder subjects relative to controls. The results indicate that relative to controls, DEGs in postmortem mood disorder tissue are enriched with TF motifs known to regulate expression of toll-like receptor signaling genes, cellular homeostatic control genes, and genes involved in cellular and brain developmental processes.
METHODS

Localization of brain gray matter loss in mood disorders
To identify the brain's most anatomically proximate regional involvement in mood pathology, with the goal of targeting the identified pathological sites for postmortem transcriptomics, a large scale meta-analysis of voxel based morphometry studies of gray matter loss in mood disorders was first performed using the anatomical likelihood estimation approach. This approach models the spatial uncertainty associated with each reported location for significant between-group differences (Eickhoff et al. 2009 ), and further compute the convergence across all included experiments by the union of the ensuing probabilistic model relative to a null-distribution and thereby reflecting a random spatial association between the findings of different experiments (Eickhoff et al. 2012) . The brain region exhibiting the most statistically significant gray matter loss associated with mood disorders using the anatomical likelihood estimation was the right anterior insula cortex gray matter ( Figure. 1A) (Jabbi et al. unpublished observation) . The identified anterior insula region exhibiting gray matter loss in mood disorder brain imaging cohorts was used for our robust image-guided transcriptomics by guiding dissection of the imaging identified reduced anterior insula volume in the independent postmortem mood disorder cohorts towards the goal of realizing a more anatomically precise RNA-seq study of the putative pathological tissue associated with mood disorder diagnoses.
Postmortem variable factor-analysis
To explore morbidity related gene expression profiles beyond classic case vs control comparisons, we conducted a factor analysis to identify higher-order composite variables included with the postmortem data. For each postmortem sample, the donor data includes specific mood disorder and comorbid lifetime-Axis-I comorbidity (i.e. number of lifetime-Axis-I diagnostic occurrences, Brain Dissection: The NIMH Human Brain Collection Core (HBCC) provided the Postmortem samples for which informed consents are acquired according to NIH IRB guidelines. Clinical characterization, neuropathology screening, and toxicology analyses followed previous protocols (Martin et al. 2006) . We applied robust image-guided transcriptomics as follows: first, the region of interest targeted for dissection was defined as portion of right AIC encompassing the identified reduced GMV in the completed meta-analysis by the authors. Electronic image slices of the imaging-defined GMV loss volumes were then shared with the HBCC neuropathologist who used these images to guide dissection of coronal tissue slabs of each postmortem donor brain at the NIH clinical center. The dissected regional volume corresponded to the anterior portion of the insula where the caudate and putamen are approximately equal in size and tissue was dissected from this section for each brain for use in RNA-sequencing ( Figure. 1A-D) . The region of interest results of gray matter volume reduction in right anterior insula previously observed (Jabbi et al. unpublished observations) to be associated with mood disorder diagnoses in the imaging metaanalysis ( Figure. 
RNA-Extraction:
All dissected tissues were separately pulverized and 50 mg aliquoted from each sample for standardized total RNA processing. Specifically, RNeasy Lipid Tissue Mini Kit (50) was used for RNA purification using the 50 RNeasy Mini Spin Columns, Collection Tubes (1.5 ml and 2 ml), QIAzol Lysis Reagent, RNase-free Reagents and Buffers kit from Qiagen. DNase treatment was applied to the purified RNA using Qiagen RNase-Free DNase Set (50) 
Differential Gene Expression Analysis:
The reads were pseudo-aligned to the human reference transcriptome (GRCh38-gencode) using kallisto (Bray 2016) , and gene-level abundances were obtained. The abundances were normalized using DESeq2, and transformed with variance stabilizing transformation (defined here as a transformation or normalization technique that seeks to create more homoscedasticity, and thereby having a closer to constant variance in the dataset regardless of the mean expression value (Love et al. Genome Biology 2014) .
We performed differential expression analysis based on the negative binomial distribution for modeled gene counts using DESeq2. RIN-values were included in the DESeq2 design matrix as a covariate to control for its potentially confounding effects. We performed differential expression EnrichR (Kuleshov et al. 2016 ) was used to identify TF motifs enriched upstream of our DEGs. We focused on the top 10 most significant TF motifs found in the database of 579 PFMs associated with the DEGs observed in our DESeq2 results dataset for each of the 3 analytical contrasts (i.e. BD vs controls; MDD vs controls; pooled mood disorder cohort with high Axis-I comorbidity vs pooled mood disorder cohort with low Axis-I comorbidity). TF motifs within the JASPAR 2018 that were found to be enriched at adjusted p-value cutoff of 0.1 were identified as enriched TFs and for each of the 3 DEG contrasts (i.e. BD vs controls; MDD vs controls; low vs high Axis-I comorbidity) we selected the top 10 TF motifs (see Figures 2&3) .
RESULTS
Postmortem Variability
Factor analysis identified two higher-order factors representing 1) number of Axis-1 diagnoses showing Bonferroni corrected pairwise-comparison differences between MDD > controls (p<0.0001); BD > controls (p<0.0001); and BD > MDD (p = 0.004).
DEGs and JASPAR TF motif identification of mood disorder group-related differential gene expression
We found 456 differentially expressed genes for the bipolar vs controls ( Supplementary Table   1 ) and 2722 differentially expressed genes for major depressive disorder vs controls ( Supplementary Table 2 ) in our analyses. Further analysis that includes DEG results from more than one brain region in the same mood disorder samples will help explain if our observed higher number of DEGs in major depressive vs control samples relative to bipolar disorder vs controls is pathophysiologically relevant in a region-specific manner. By first directly comparing TF motifs found in BD vs control DEGs, we found DEGs were enriched with motifs of MIB2, Esrrb, TEAD2, ZBTB7A, MIR210, MZF1, KLF11, SMAD4, ZNF148, and TEAD4 TFs ( Figure. 2A) . Direct comparisons between MDD vs controls identified enriched motifs of MIR210, TEAD4, SP4, TEAD2, TCFAP2A, SP1, SP3, PCBP1, HNF1B, and Esrrb TFs (Figure. 2B) .
Given our approach to examine the hierarchical relationship between TF motifs and DEGs profiles associated with the degree of psychiatric morbidity/Axis-I comorbidity in the two mood disorder cohorts, we first used principal axis factoring to identify Axis I comorbidity (i.e. total number of psychiatric diagnoses), and manner of death by suicide or non-suicide (together comprising the factor we refer to here as the Axis-I comorbidity burden) to compositely explain variability in (i) Axis-I comorbidity burden, and (ii) suicide completion. We included this factor in our analysis using a split half approach of high vs low Axis-I comorbidity burden to identify TF motifs for DEG profiles for Axis-I comorbidity burden. We found DEGs in the pooled BD & MDD donor samples (i.e. without control donors) and these DEGs were enriched in TF motifs of NFATC2, GABPA, HMAGA1, NR3C1, GTF2I, IRF2, POU1F1, SAMD9L, SNAI1, and CBEPB ( Figure. 3) . Collectively, these TFs are known to regulate expression of toll-like receptor signaling genes, cellular homeostatic control genes, and genes involved in embryonic, cellular and neurodevelopmental processes.
Specifically, comparing BD vs controls revealed differentially expressed genes with enriched motifs for TFs involved in regulating a) immune response and antigen processing (i.e. (Figure 2B) . Restricting our analysis to comparing mood disorder donors with high Axis-I comorbidity vs mood disorder donors scoring low on Axis-I comorbidity, we found differentially expressed genes with enriched motifs for TFs involved in regulating a) inflammatory and immune response and toll-like receptor signaling, b) embryonic and cellular developmental processes, and c) cellular and peripheral homeostatic control (see Figure 3 for specific regulatory functions for each of the identified TFs). When comparing DEGs in high vs low Axis-I comorbidity in mood disorders, we found 3 motifs for master TFs implicated in regulation an array of functions including general transcriptional regulation through interaction with basal transcriptional machinery (i.e. G2FTI), master transcriptional co-activation of several other TFs (i.e. CREBBP), and a master TF that regulates inflammatory, cellular developmental, and glucocorticoid gene expression processes (i.e. NR3C1) (see Figure 3 for specific regulatory functions for each of the identified TFs).
DISCUSSION
Understanding the molecular substrates for regional brain abnormalities underlying major mental illness such as mood disorders, which affects over 10% of the population across the lifetime, will not only contribute to better mechanistic understanding of the neurobiological bases for behavioral pathologies (Nestler 2015; Sahin & Sur Science 2015; Torre-Ubieta et al. 2018; Jabbi & Nemeroff 2019 ) but will also be essential for novel drug design (Changeaux 2017).
In the present study, we applied robust image-guided transcriptomics by extracting RNAsamples from a precisely localized anterior insula region exhibiting the strongest degree of gray matter loss in mood disorders. This robust image-guided transcriptomics study therefore integrated RNA-seq characterization of gene expression abnormalities in an anatomically abnormal region in mood disorders and allowed testing of the hypothesis that transcription factor gene expression profiles will be altered/enriched in the postmortem anterior insula cortex of mood disorder subjects relative to controls. We found that comparing BD vs controls revealed DEGs MIR120, TEAD2, TEAD4 and Esrrb) suggesting possible specific as well as overlapping TF motifs for BD & MDD. If replicated, the identified TF motifs associated with DEGs in mood disorder diagnoses and overall disease morbidity will likely reveal a vulnerability in the general transcriptional pathway mechanism in mood disorder disease states.
The identified enriched TF motifs are known to regulate expression of toll-like receptor signaling genes, cellular homeostatic control genes, and embryonic and cellular including neurodevelopmental gene networks found to be differentially expressed in BD vs controls, MDD vs controls, and in high Axis-I comorbid mood disorder individuals vs low Axis-I comorbidity mood disorder individuals. We found putative hierarchical TF regulatory involvement in the gene expression landscapes associated with BD and MDD diagnoses, such that enrichments of master transcription factors were predominantly associated with the gene expression landscape in elevated mood disorder morbidity, thereby echoing previous work (Tsigelny et al. 2013; Lee & Young 2013; Changeaux 2017; Lambert et al. 2018; Chen C et al. 2019) .
Traditional analyses of differential gene expression often assumes that genes of similar average expression strengths will likely have similar dispersion without considering that different gene classes such as TFs that are hierarchically programmed to functionally regulate other gene classes (Love et al. 2014; Anders & Huber 2010) . Our current identification of enriched TF motifs known to regulate the expression of toll-like receptor signaling pathway genes, cellular homeostatic control genes, and embryonic as well as cellular and neurodevelopment pathway genes in mood disorder diagnostic phenotypes, suggests a putative hierarchical involvement of the identified TFs in the neurobiological abnormalities underlying mood disorder phenotypes.
Our current robust image-guided transcriptomics approach illustrates associations rather than direct testing of the causal involvements of the identified TF motifs in 1) the developmental or disease-driven emergence of the anatomical gray matter loss identified in the anterior insula of mood disorder individuals, and 2) the observed postmortem differential gene expression landscape measured within the anterior insula in mood disorder morbidity. Anatomical abnormalities in the anterior insula are not specific to mood disorder diagnoses per se, but involved in several neuropsychiatric diagnoses including anxiety, psychosis, substance use and eating disorders (Goodkind et al. 2016; Janiri et al. 2019 ), suggesting the importance of including other more mood disorder-specific regional anatomical brain abnormalities in future transcriptomics studies.
Furthermore, our approach to target the anterior insula gray region that exhibited a reduction in volume in living mood disorder individuals for tissue dissection and subsequent RNA-sequencing in an independent postmortem sample, does not address if the reduced insula volume was present in the currently studied postmortem mood disorder sample. Future studies need to explore integrating anatomical and gene expression abnormalities in the same postmortem brain samples across brain regions to directly link anatomical abnormalities with underlying molecular genetic regulatory abnormalities in the same postmortem brains.
Our bulk tissue RNA-sequencing approach does not account for the role of specific celltypes in defining TF regulatory involvements in mood disorder transcriptomics. Therefore, exploration of cell-type-specific regional brain analysis in mood disorders across the lifespan will also advance our understanding of the role of TFs in the pathogenesis of mood disorders. Although our current study identified relevant TF involvement in regulatory gene expression signatures for mood disorders, inclusion of a comparison psychiatric cohort without mood symptoms such as schizophrenia in future studies will help address the specificity of the identified TF targets for mood disorder therapeutics. These limitations notwithstanding, our current focus on the anterior insula given its identification as the region exhibiting the strongest statistically significant gray matter loss associated with mood disorder diagnoses, provides a framework for integrative studies of anatomical and molecular abnormalities underlying prevalent brain diseases.
In conclusion, we applied robust image-guided transcriptomics to characterize the roles of specific TFs in phenotypic mood disorder morbidity. Our findings successfully demonstrated that the postmortem gene expression landscape is associated with (1) the magnitude of mood disorder morbidity, in a putative abnormal brain anatomically compromised region in mood disorder diagnoses;
(2) with enriched TF motifs known to regulate general transcriptional processes, immune responsive, cellular homeostatic control, embryonic and neuronal development functions.
Together, these findings illustrate that studies of gene regulatory networks, in addition to studying the functional profiles of the several genes these TF regulatory networks control/transcribe, has the potential to elucidate the hierarchical organizational principles of gene expression landscapes driving major psychiatric disorders and thereby accelerate novel pharmacological target discovery. 
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